共 60 条
[1]
Carbone M(2019)Mesothelioma: scientific clues for prevention, diagnosis, and therapy CA Cancer J Clin 69 402-429
[2]
Adusumilli PS(2020)Immunotherapy in malignant pleural mesothelioma Front Oncol 10 187-1273
[3]
Alexander HR(2017)Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial Lancet Oncol 18 1261-253
[4]
de Gooijer CJ(2019)Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial Lancet Oncol 20 239-5492
[5]
Borm FJ(2019)Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, japanese phase ii study in malignant pleural mesothelioma (MERIT) Clin Cancer Res 25 5485-270
[6]
Scherpereel A(2019)Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial Lancet Respir Med 7 260-1390
[7]
Baas P(2010)Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma Am J Respir Crit Care Med 181 1383-776
[8]
Maio M(2018)Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human Clin Cancer Res 24 766-1031
[9]
Scherpereel A(2016)Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma Am J Respir Crit Care Med 193 1023-201
[10]
Calabrò L(2001)Localised spontaneous regression in mesothelioma–possible immunological mechanism Lung Cancer 32 197-1549